Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare liver diseases, with its lead product LIVMARLI (maralixibat) approved for treating cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). The company operates in the orphan drug space with high pricing power ($300K+ annual treatment costs) and limited competition, generating approximately $300M in revenue with 75%+ gross margins despite ongoing operating losses as it scales commercialization infrastructure across US and European markets.
Mirum generates revenue through direct sales of LIVMARLI to specialty pharmacies and hospitals treating ultra-rare pediatric liver disease patients. The orphan drug designation provides 7-year market exclusivity, minimal price sensitivity due to lack of alternatives, and favorable reimbursement from payers given severe disease burden. With patient populations under 1,000 per indication globally, the company employs a targeted commercial strategy using specialized sales teams rather than mass marketing. Gross margins exceed 75% as manufacturing is outsourced and COGS remain low relative to premium pricing justified by transformative clinical benefits (reducing debilitating itching that drives liver transplants). Operating losses reflect ongoing investment in clinical trials for label expansions, regulatory submissions in new geographies, and building commercial infrastructure ahead of revenue inflection.
LIVMARLI quarterly prescription volume and net revenue per patient (tracking penetration of ~600 diagnosed ALGS patients in US)
Clinical trial readouts for label expansion opportunities (volixibat data, chenodiol proof-of-concept results)
European commercial launch execution and reimbursement approvals in key markets (Germany, UK, France)
FDA regulatory decisions on supplemental indications or pediatric age expansions
Analyst estimates revisions for peak sales potential (current Street estimates range $800M-$1.2B)
M&A speculation given attractive orphan drug portfolio and $5.3B market cap in consolidating rare disease sector
Orphan drug pricing scrutiny from Congress and CMS could pressure reimbursement rates despite current favorable environment for rare disease therapies
Gene therapy advances for ALGS and PFIC could provide curative alternatives within 5-10 years, obsoleting chronic symptomatic treatments like LIVMARLI
Small patient populations limit revenue ceiling to $1B+ range, constraining long-term growth without successful pipeline expansion beyond current indications
Ipsen's Bylvay (odevixibat) competes directly in PFIC indication with similar mechanism, creating pricing pressure and market share battles
Albireo Pharma (acquired by Ipsen 2024) strengthens competitor's rare hepatology franchise and commercial infrastructure
Larger pharmaceutical companies (Takeda, Alexion/AstraZeneca) expanding into rare disease space could out-resource Mirum in physician education and market development
Negative operating cash flow and -26% operating margin require continued cash burn until profitability achieved (estimated 2027-2028 based on current trajectory)
Debt-to-equity of 1.09x creates refinancing risk if capital markets tighten before company reaches sustained profitability
Dependence on equity markets for future financing if clinical trials require additional capital or commercial ramp takes longer than projected
low - Rare disease treatments for life-threatening pediatric conditions exhibit minimal demand elasticity regardless of economic conditions. Patients require therapy irrespective of GDP growth, and payers cover orphan drugs given lack of alternatives and severe disease burden. The ultra-rare patient population (~1,000 globally per indication) means market size is biologically constrained rather than economically driven.
Rising rates create moderate valuation pressure on pre-profitable biotech stocks as investors discount future cash flows more heavily and rotate toward current income. However, Mirum's strong balance sheet (3.31x current ratio, minimal debt at 1.09 D/E) and approaching profitability reduce financing risk. Higher rates may slow M&A activity in the sector, potentially delaying exit opportunities for investors. The company's commercial-stage status with established revenue partially insulates it from the severe multiple compression affecting early-stage biotechs.
minimal - The company operates with low financial leverage and strong liquidity. Rare disease drugs face minimal reimbursement pressure even during credit tightening as payers prioritize coverage for severe pediatric conditions. Specialty pharmacy distribution partners maintain stable credit access. Patient access programs are internally funded rather than credit-dependent.
growth - The stock attracts biotech growth investors focused on commercial-stage rare disease companies approaching profitability inflection. The 96% one-year return and 80%+ revenue growth appeal to momentum investors, while the orphan drug exclusivity and high gross margins attract fundamental growth managers. Institutional ownership likely concentrated among healthcare-focused funds (Perceptive Advisors, RTW Investments, RA Capital) rather than broad index investors. The pre-profitable status and high valuation multiples (11.3x P/S) deter value investors, while lack of dividends excludes income-focused strategies.
high - Small-cap biotech with $5.3B market cap exhibits elevated volatility driven by binary clinical/regulatory events, quarterly earnings surprises, and sector rotation. Limited float and concentrated institutional ownership amplify price swings. The stock's 43% three-month return demonstrates momentum-driven volatility. Beta likely exceeds 1.5x relative to broader market given biotech sector characteristics and company-specific event risk around trial readouts and commercial execution.
